Phreesia, Inc. (NYSE:PHR) SVP David Linetsky Sells 1,716 Shares of Stock

Phreesia, Inc. (NYSE:PHR) SVP David Linetsky sold 1,716 shares of the firm’s stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $23.25, for a total transaction of $39,897.00. Following the completion of the transaction, the senior vice president now directly owns 203,318 shares of the company’s stock, valued at approximately $4,727,143.50. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

David Linetsky also recently made the following trade(s):

• On Tuesday, July 16th, David Linetsky sold 1,820 shares of Phreesia stock. The shares were sold at an average price of $23.74, for a total transaction of $43,206.80.
• On Thursday, June 20th, David Linetsky sold 66 shares of Phreesia stock. The shares were sold at an average price of $19.73, for a total transaction of $1,302.18.
• On Tuesday, June 18th, David Linetsky sold 41 shares of Phreesia stock. The shares were sold at an average price of $19.20, for a total transaction of $787.20.

Phreesia Stock Up 1.9 %

Shares of NYSE:PHR opened at $23.76 on Friday. The company’s fifty day moving average price is $23.63 and its 200 day moving average price is $22.75. Phreesia, Inc. has a 12 month low of $12.05 and a 12 month high of $29.16. The company has a current ratio of 1.77, a quick ratio of 1.77 and a debt-to-equity ratio of 0.03.

Analyst Ratings Changes

PHR has been the subject of several recent research reports. Needham & Company LLC reissued a “buy” rating and issued a $29.00 price target on shares of Phreesia in a research report on Thursday, September 5th. JPMorgan Chase & Co. raised their price objective on shares of Phreesia from $27.00 to $28.00 and gave the company an “overweight” rating in a report on Monday. Canaccord Genuity Group restated a “buy” rating and issued a $34.00 price objective on shares of Phreesia in a report on Thursday, September 5th. Truist Financial raised their price objective on shares of Phreesia from $29.00 to $31.00 and gave the company a “buy” rating in a report on Friday, September 6th. Finally, Stephens restated an “overweight” rating and issued a $28.00 price objective on shares of Phreesia in a report on Friday, May 31st. One equities research analyst has rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. According to MarketBeat.com, Phreesia has an average rating of “Moderate Buy” and a consensus price target of $29.42.

Institutional Investors Weigh In On Phreesia

Several hedge funds and other institutional investors have recently bought and sold shares of PHR. nVerses Capital LLC increased its stake in Phreesia by 76.5% in the second quarter. nVerses Capital LLC now owns 3,000 shares of the company’s stock valued at $64,000 after purchasing an additional 1,300 shares during the period. Russell Investments Group Ltd. increased its stake in Phreesia by 5,462.3% in the fourth quarter. Russell Investments Group Ltd. now owns 3,838 shares of the company’s stock valued at $89,000 after purchasing an additional 3,769 shares during the period. EntryPoint Capital LLC acquired a new position in Phreesia in the first quarter valued at $169,000. Quadrature Capital Ltd acquired a new position in Phreesia in the first quarter valued at $202,000. Finally, Lombard Odier Asset Management USA Corp acquired a new position in Phreesia in the second quarter valued at $202,000. 92.10% of the stock is currently owned by institutional investors and hedge funds.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.